BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 16207990)

  • 1. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Fothergill A; Ghannoum M; Manavathu E; Ostrosky-Zeichner L; Pfaller M; Rinaldi M; Schell W; Walsh T
    J Clin Microbiol; 2005 Oct; 43(10):5243-6. PubMed ID: 16207990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
    Espinel-Ingroff A
    J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity (MIC and MFC) of voriconazole, amphotericin B, and itraconazole against 192 filamentous fungi: the GISIA-2 study.
    Morace G; Drago M; Scaltrito MM; Conti S; Fanti F; Polonelli L;
    J Chemother; 2007 Oct; 19(5):508-13. PubMed ID: 18073149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN;
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality control guidelines for amphotericin B, Itraconazole, posaconazole, and voriconazole disk diffusion susceptibility tests with nonsupplemented Mueller-Hinton Agar (CLSI M51-A document) for nondermatophyte Filamentous Fungi.
    Espinel-Ingroff A; Canton E; Fothergill A; Ghannoum M; Johnson E; Jones RN; Ostrosky-Zeichner L; Schell W; Gibbs DL; Wang A; Turnidge J
    J Clin Microbiol; 2011 Jul; 49(7):2568-71. PubMed ID: 21543581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
    Espinel-Ingroff A; Arthington-Skaggs B; Iqbal N; Ellis D; Pfaller MA; Messer S; Rinaldi M; Fothergill A; Gibbs DL; Wang A
    J Clin Microbiol; 2007 Jun; 45(6):1811-20. PubMed ID: 17428932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD; Kiraz N
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds.
    Espinel-Ingroff A; Fothergill A; Ghannoum M; Manavathu E; Ostrosky-Zeichner L; Pfaller MA; Rinaldi MG; Schell W; Walsh TJ
    J Clin Microbiol; 2007 Jul; 45(7):2180-2. PubMed ID: 17475760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods.
    Linares MJ; Charriel G; Solís F; Rodriguez F; Ibarra A; Casal M
    J Clin Microbiol; 2005 Jan; 43(1):250-3. PubMed ID: 15634979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
    Espinel-Ingroff A; Johnson E; Hockey H; Troke P
    J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of filamentous fungi to itraconazole, voriconazole and posaconazole by Clinical and Laboratory Standards Institute reference method and E-test.
    Kondori N; Svensson E; Mattsby-Baltzer I
    Mycoses; 2011 Sep; 54(5):e318-22. PubMed ID: 20557462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
    Wang HC; Hsieh MI; Choi PC; Wu CJ
    J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
    Johnson EM; Szekely A; Warnock DW
    J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J; Peláez T; Alcalá L; Bouza E
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi.
    Espinel-Ingroff A
    J Clin Microbiol; 2001 Apr; 39(4):1360-7. PubMed ID: 11283057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of disk diffusion, E-test and broth microdilution test in determination of susceptibility of Aspergillus species to amphotericin B, itraconazole and voriconazole.
    Ozkutuk A; Ergon C; Metin DY; Yucesoy M; Polat SH
    J Chemother; 2008 Feb; 20(1):87-92. PubMed ID: 18343749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
    Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
    Lewis RE; Wiederhold NP; Klepser ME
    Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.